What we did

Capitalmind Investec has actively supported Sofiproteol in negotiating with Ceva Santé Animale, providing valuation guidance, execution support (data room management, deal coordination, carve out preparation & structuring, etc.), mapping out negotiation arguments, supporting the team in this disposal process and more generally defining tactics to make this deal happen in a very short period.

This deal is the fourth advised by Capital Partner on behalf of Sofiproteol since 2011.

About the deal

Sogeval (part of the Animal Division of Sofiproteol) is the 5th veterinary drug firm in France, developing, producing and marketing veterinary products (for companions animals and livestock production) under its own brands and for third-party companies. Employing circa 300 people, Sogeval (and its US, UK subsidiaries) reported over €85m of sales in 2013.

Ceva Santé Animale was founded in 1999 and is the world’s 9th-largest veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Thanks to its international presence, its 2012 sales exceeded €600 million.

The combination of Sogeval with Ceva Santé Animale will strongly contribute to create one of the world leaders in veterinary pharmacy.